Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gabapentin Extended Release for Hot Flashes (Breeze3)
NCT01080300Phase 3Completed
- Sponsor
- Assertio
- Start
- Aug 2010
- Primary completion
- Sep 2011
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of gabapentin in hot flashes, sponsored by Assertio. Primary endpoints: Average Daily Frequency of Moderate to Severe Hot Flashes at 12 weeks and Average Daily Severity Score of Moderate to Severe Hot Flashes at 12 weeks. Started Aug 2010; status: completed.
02
Drugs
gabapentin
03
Conditions
hot flashes
Beyond the preview
Go deeper on NCT01080300.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01080300.